SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce Holdings is trending as a key beneficiary of global rearmament and surging civil aerospace demand, highlighted by a significant engine order from Delta Air Lines and numerous defense contracts. The community anticipates strong upcoming earnings, fueled by these catalysts and long-term optimism for its small modular reactor (SMR) and power systems solutions for data centers.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet ($STRK) is trending as its ecosystem displays robust growth with record TVL and stablecoin supply, sparking discussion around its ZK-STARKs technology providing quantum resistance and privacy features for institutional adoption. The community remains convicted in its long-term vision as critical infrastructure for Ethereum scaling and BTCFi, further solidified by its token's expansion to Solana.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending following its latest earnings report, which, despite beating revenue and EPS, saw future profit guidance trimmed and analyst price targets cut, triggering a sharp sell-off. The community is fiercely debating whether this decline is an overreaction driven by broader 'AI panic' and M&A integration costs, or a justified repricing for an overvalued stock with concerns over declining margins.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion (INFQ) is seeing surging community interest following its NYSE debut and upcoming bell-ringing ceremony, driven by its advanced neutral-atom quantum technology, robust partnerships, and the expectation of increased trading accessibility as initial brokerage platform issues resolve.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is a focal point for investors anticipating the imminent BLA resubmission for its Duchenne Muscular Dystrophy therapy, Deramiocel, driven by robust Phase 3 data and increasing institutional ownership, alongside excitement for its promising exosome platform.

WorldFinancial

WLFI is highly contentious amid an anticipated Mar-a-Lago event with institutional players, where the community debates potential institutional adoption against ongoing congressional scrutiny and a probe into its foreign investment and governance.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending due to heightened buyout speculation, driven by the community's frustration over perceived management silence regarding crucial AUR200 pipeline updates and ongoing patent developments. This fuels anticipation of a potential acquisition, as investors weigh strategic board connections against the company's established lupus nephritis drug and promising autoimmune assets.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is actively trending as NVIDIA's recent filing revealed an exited position, sparking volatility and concern, while bulls maintain this was a strategic profit-take and point to strong institutional buying, continued AI infrastructure demand, and upcoming hyperscaler lease announcements.

Corsair Gaming, Inc. designs and supplies hardware components for personal computers. It operates through the Gamer and Creator Peripherals, and Gaming Components and Systems segments. The Gamer and Creator Peripherals segment offers gaming keyboards, mice, headsets, controllers, and gaming gear including capture cards, Stream Decks, USB microphones, studio accessories, and EpocCam software, as well as coaching and training services. The Gaming Components and Systems segment focuses on creating power supply units, or PSUs, cooling solutions, computer cases, DRAM modules, prebuilt, and custom-built gaming PCs. The company was founded by Andrew J. Paul in 1994 and is headquartered in Milpitas, CA.

Corsair Gaming Inc

Corsair Gaming is trending after reporting strong Q4 and full-year results, including an authorized $50 million share repurchase program, which has sparked a polarized debate among investors about whether the significant rally is sustainable or a manipulative pump and dump. The community is actively discussing the stock's potential for a short squeeze, its position to benefit from skyrocketing memory prices, and recent insider buying.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as a critical player in the evolving AI ecosystem, driven by its strategic partnership with Palantir, involvement in U.S. defense AI initiatives, and expansion into AI robotics. Amidst a broader market sell-off in AI, the community is debating whether the recent dip represents an exceptional buying opportunity, citing the company's strong fundamentals and vital role in training AI for various sectors, including emerging humanoid AI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biotech-focused investor Cormorant Asset Management rebuilt its stake above 6% on Tuesday.</li><li>Cormorant disclosed ownership of 4.36 million shares, up from about 2 million shares in October.</li><li>Retail sentiment flipped to ‘extremely bullish’ from ‘extremely bearish’ on Stocktwits, and message volume surged more than 900%.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. jumped 11% on Tuesday, marking the stock’s biggest rally in over a month, after a biotech-focused investment firm rebuilt its stake amid heightened buzz among retail traders speculating a possible takeover.<h2 class="st-heading-2">Cormorant Lifts MoonLake Stake Above 6%</h2>A Schedule 13G filing on Tuesday showed Cormorant Asset Management reported ownership of 4.36 million Class A ordinary shares in MoonLake Immunotherapeutics, representing a 6.1% stake as of Dec. 31, 2025. The stake increased from about 2 million shares, or 3.14%, disclosed in October 2025 filings, after the firm had previously reduced its position below the 5% reporting threshold.Cormorant Asset Management is a biotech-specialised investment management firm with stakes in Praxis Precision Medicines, BridgeBio Oncology Therapeutics, Edgewise Therapeutics, and Metsera, which was acquired last year by Pfizer, among others.According to data from Quiver Quantitative, the firm reported holdings in 43 stocks as of Sept. 30, 2025, with an estimated portfolio value of about $1.45 billion.<h2 class="st-heading-2">FDA Momentum Builds Around Sonelokimab</h2>Earlier this month, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company’s lead investigational therapy, Sonelokimab, for moderate-to-severe palmoplantar pustulosis. The company plans to pursue a biologics license application for Sonelokimab in hidradenitis suppurativa in the second half of 2026.Last month, MoonLake said a Type B meeting with the FDA confirmed its clinical evidence strategy for Sonelokimab in hidradenitis suppurativa. Following that update, several brokerages raised price targets or upgraded the stock, though&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-erases-most-of-2025-loses-wall-street-retail-bets-on-fda-feedback-for-sonelokima/cmU1QhGR471">Goldman Sachs</a> downgraded MoonLake to ‘Sell’ last month, citing “high risk” around approvability in hidradenitis suppurativa.The company is scheduled to host an investor day on Feb. 23, at which it plans to provide updates on the clinical development and regulatory pathway for Sonelokimab across multiple inflammatory disease indications.<h2 class="st-heading-2">Stocktwits Buzz Erupts Around MLTX</h2>On Stocktwits, retail sentiment for MLTX flipped to ‘extremely bullish’ from ‘extremely bearish’ over the past day amid over a 900% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_b0740594f9.webp" alt="mltx ss.png" width="971" height="140"><figcaption>MLTX sentiment and message volume as of February 17 | Source: Stocktwits</figcaption></figure>One user said the Cormorant filing has “fundamentally broken” the short thesis. “Cormorant—who knows the science better than anyone—just admitted the "Bear Thesis" was wrong by buying back in at $12-$16.”<stembedurl>https://stocktwits.com/septrading/message/645184471</stembedurl>Another user said, “I can’t stop thinking that we get a PR of some sort, even a little teaser, PM tomorrow AM” ahead of the company’s investor day.<stembedurl>https://stocktwits.com/BOOPIE2020/message/645177386</stembedurl>A third user said, “I have to say that something may be coming..This price action today was solid coupled with the high after hours volume. Someone is accumulating.”<stembedurl>https://stocktwits.com/TDMF123/message/645174457</stembedurl>A separate user said they were watching for either a buyout announcement or positive regulatory news this week, while another argued MoonLake would need to trade higher before attracting interest from a large pharmaceutical acquirer.<stembedurl>https://stocktwits.com/Warren_8/message/645090086</stembedurl><stembedurl>https://stocktwits.com/Newcar/message/645134185</stembedurl>One user pointed to recent travel activity involving Merck’s corporate jet, hinting at a potential takeover by the big pharma firm and noted multiple trips to Zurich, where MoonLake is headquartered.&nbsp;<stembedurl>https://stocktwits.com/Bigpapa46/message/645006814</stembedurl>MLTX stock has risen 33% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Equity

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $100.00

HC Wainwright upped their price objective on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday...

BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer

Oppenheimer boosted their price target on BridgeBio Pharma from $81.00 to $83.00 and gave the stock an "outperform" rating in a research note on Friday...

Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an "overweight" rating in a research note on Friday...

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the company's stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an...

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week High - Here's What Happened

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High - What's Next...

BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia

BridgeBio Pharma (NASDAQ:BBIO) detailed positive Phase 3 results from its PROPEL-3 clinical trial evaluating oral infigratinib for children with achondroplasia, describing what executives called...

<ul class="summary-bullets"><li>The study met its main goal by demonstrating a meaningful increase in annualized height velocity compared with placebo.&nbsp;</li><li>Secondary measures reinforced those results, including improvements in absolute growth rate and height Z-scores relative to achondroplasia norms.</li><li>BridgeBio said it intends to meet with regulators to discuss filing a New Drug Application in the U.S.</li></ul>BridgeBio Pharma Inc. (BBIO) on Thursday reported encouraging phase-3 study data for its experimental oral therapy infigratinib, saying the drug improved growth outcomes in children with achondroplasia, a genetic form of dwarfism.&nbsp;The topline findings stem from PROPEL 3, a global, yearlong Phase 3 trial that enrolled children ages 3 to younger than 18 with open growth plates. Participants were randomly assigned at a 2:1 ratio to receive infigratinib or placebo, with statistically significant improvements across key growth measures through Week 52.<h2 class="st-heading-2">Primary And Secondary Endpoints</h2>The study met its main goal by demonstrating a meaningful increase in annualized height velocity compared with placebo. Children receiving the therapy grew faster on average, with a treatment benefit of more than 2 centimeters per year compared with placebo.&nbsp;Secondary results supported the primary findings, including improvements in absolute growth rate and height scores relative to achondroplasia norms. The company said the magnitude of improvement ranks among the strongest seen in randomized studies for the condition.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/BBIO">BridgeBio Pharma's stock</a> traded over 17% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘neutral’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Body Proportionality Findings&nbsp;</h2>In an analysis of children younger than 8, infigratinib also achieved a statistically significant improvement in upper-to-lower body proportionality compared with placebo.&nbsp;<blockquote>“In the broadest age range studied to date, oral infigratinib has demonstrated the highest and most significant improvement in annualized growth velocity, along with the first statistically significant improvement in body proportionality, in children aged 3 to 8 years, reported for any therapy approved or in development for this condition.”-Ravi Savarirayan, Global Lead Investigator, PROPEL 3</blockquote>BridgeBio said it intends to meet with regulators to discuss filing a New Drug Application in the U.S. and a Marketing Authorization Application in Europe in the second half of 2026.BBIO stock has gained over 129% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/the-big-short-investor-michael-burry-reflects-on-palantir-s-billions-in-losses-before-2020-debut/cZRTNcbR4rL">‘The Big Short’ Investor Michael Burry Reflects On Palantir’s Billions In Losses Before 2020 Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally?

The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism. 

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.71	--	--	N/A
Q3 '25	-$0.91	-$0.95	-4.71%	MISSED
Q2 '25	-$0.79	-$0.95	-19.73%	MISSED
Q1 '25	-$0.92	-$0.88	4.13%	BEAT
Q4 '24	-$1.12	-$1.40	-24.98%	MISSED

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BBIO News

BBIOBridgeBio Pharma Inc